A novel pathogenetic factor of laryngeal attack in hereditary angioedema? Involvement of protease activated receptor 1.

"Declarations Ethics approval and consent to participateThe study protocol was approved by the institutional review board of Semmelweis University of Budapest (Reg. No. 1067-5/2018/EUIG). Consent for publicationNo similar data has been or will be published or submitted elsewhere while our manuscript is under consideration at allergy, asthma and clinical immunology. Competing interestsHenriette Farkas has received research grants from CSL Behring, Shire/Takeda and Pharming and served as an advisor for these companies and BioCryst, Kalvista and Ono Pharmaceutical. László Cervenak has served as an advisor for Ono Pharmaceutical. Other authors declare no conflict of interest. Competing interests Henriette Farkas has received research grants from CSL Behring, Shire/Takeda and Pharming and served as an advisor for these companies and BioCryst, Kalvista and Ono Pharmaceutical. László Cervenak has served as an advisor for Ono Pharmaceutical. Other authors declare no conflict of interest."

"Funding Open access funding provided by Semmelweis University. This study was supported by the National Research, Development and Innovation Office Grant N K124557 and Shire Research Grant. The Institution and Investigator will provide Shire with a copy of the proposed publication or application at least forty five (45) days prior to its submission to a scientific journal."